CH3Use of Semaglutide
docx
keyboard_arrow_up
School
United States University *
*We aren’t endorsed by this school
Course
MSN 560
Subject
Medicine
Date
Dec 6, 2023
Type
docx
Pages
4
Uploaded by CountHeatTiger23
Use of Semaglutide for the Treatment of Overweight and Obesity
1
Use of Semaglutide for the Treatment of Overweight and Obesity
MSN563 Sect4 Evidence-Based Inquiry For Scholarship And Practice
Dr. Katie Bull
January 25, 2023
Use of Semaglutide for the Treatment of Overweight and Obesity
2
Use of Semaglutide for the Treatment of Overweight and Obesity
Introduction
Obesity continues to be one of the most prevalent health problems worldwide. According
to CDC, the criteria for being overweight is a BMI of more than 25 and more than 30 obesity.
(CDC, 2021). It was estimated by World Health Organization (WHO) that adults affected by
obesity in 2016 were 650 million and almost 2 billion overweight worldwide. Those statistics
continue to grow and the COVID-19 pandemic may have worsened this problem. In 2020, Obese
individuals were noted to have a higher risk of death when infected with Covid-19. It is
estimated that by 2030 in the US, 1 in 4 adults will have severe obesity. (WHO, 2016)
Obesity is considered a chronic disease that continues to relapse throughout an adult’s
lifetime and usually starts in childhood. It is a common health problem that is not considered
serious by many. It is associated with chronic diseases such as Hypertension, High-Cholesterol,
Type 2 Diabetes, Sleep disorders, and some types of Cancer among others. Poor mental health
can also be an outcome of Obesity leading to depression. It affects almost every organ in the
body, eventually leading to an increase in morbidity and mortality rate and ultimately
significantly impacting healthcare costs. (Bergmann et al, 2022). Approximately $147 billion per
year is spent on healthcare costs related to obesity (CDC, 2021). Over the next 10 years, it is
projected that half of the population will be obese.
(Finkelstein et al, 2012).
Use of Semaglutide for the Treatment of Overweight and Obesity
3
Overview of the Problem
Management of weight is very important when it comes to living a healthy lifestyle, and
avoiding the risks of getting complications related to obesity. A diet reduced in calories with
regular exercise may help in maintaining the ideal body weight. In some cases, a more drastic
way to lose body fats is considered such as bariatric surgery along with modifying diet. Although
a change in lifestyle with diet and exercise is possible, long-term management of weight loss is
very difficult to achieve. A newly developed pharmacological intervention to treat obesity and
obesity-related health issues Subcutaneous semaglutide is approved by FDA as an adjunct
therapy to lifestyle modifications for people who are overweight or have obesity based on body
weight and body mass index. It resulted in more weight loss than placebo. Weight loss with
semaglutide occurs through an increase in the feeling of being full, in combination with glycemic
control, semaglutide’s action on GLP-1 stimulates insulin secretion and suppresses glucagon
secretion when blood glucose levels are high. The safety and efficacy of semaglutide in
overweight and obese have been demonstrated in the Semaglutide Treatment Effect in People
with obesity. It is the first FDA-approved GLP-1 receptor agonist for chronically obese adults.
(Smith et al, 2022)
References
Bergmann, NC, Davies, MJ, Lingvay, I, Knop, FK. Semaglutide for the treatment of Overweight
and Obesity: A review. Diabetes Obes Metab. 2023; 25( 1): 18- 35. doi:10.1111/dom.14863
Your preview ends here
Eager to read complete document? Join bartleby learn and gain access to the full version
- Access to all documents
- Unlimited textbook solutions
- 24/7 expert homework help
Use of Semaglutide for the Treatment of Overweight and Obesity
4
Centers for Disease Control and Prevention. (2021). Overweight and Obesity.
https://www.cdc.gov/obesity/index.html
Finkelstein, E. A., Khavjou, O. A., Thompson, H., Trogdon, J. G., Pan, L., Sherry, B., &
Dietz,W. (2012). Obesity and severe obesity forecasts through 2030. American Journal of
Preventive Medicine, 42(6), 563–570. doi: 10.1016/j.amepre.2011.10.026
Smith I, Hardy E, Mitchell S, Batson S. Semaglutide 2.4 Mg for the Management of Overweight
and Obesity: Systematic Literature Review and Meta-Analysis. Diabetes Metab Syndr Obes.
2022;15:3961-3987 https://doi.org/10.2147/DMSO.S392952